Apparently the study cited by My69Z killed investo
Post# of 147672
(Total Views: 451)
Posted On: 09/15/2024 11:51:40 AM
Re: KenChowder #146372
Apparently the study cited by My69Z killed investor interest, among other things, though as I read it the final paragraphs didn't seem to justify the conclusions:
"A trial by Safadi et al. [20] found that Aramchol was associated with a significant dose-dependent improvement in liver function. Patients treated with high-dose Aramchol had a significant reduction of symptoms related to liver cell failure compared with placebo. It was also found that daily administration of 300 mg Aramchol was tolerable and safe and causes a significant reduction in reduces liver fat content in patients with NAFLD. However, the short therapeutic protocol of the trial represented a strong limitation to estimate the clinical effect of Aramchol on liver fat.
In a 1-year ARREST study [26], Aramchol was found to reduce liver fat and improve the biochemical markers of the liver. The drug was also found to reduce liver fibrosis in a dose-response pattern. Administration of Aramchol 600 mg demonstrated higher rates of NASH resolution and fibrosis reduction with excellent safety outcomes....
Conclusions
Aramchol was a safe and tolerable drug for use in patients with NAFLD. However, it was not superior to the placebo at reducing the biochemical liver markers."
Whatever, what is is, the stock is mired around 4 bucks and following two sizable reverse splits still has around 700 million shares outstanding, meaning the share count started in the billions. And here I thought out share count was high...
"A trial by Safadi et al. [20] found that Aramchol was associated with a significant dose-dependent improvement in liver function. Patients treated with high-dose Aramchol had a significant reduction of symptoms related to liver cell failure compared with placebo. It was also found that daily administration of 300 mg Aramchol was tolerable and safe and causes a significant reduction in reduces liver fat content in patients with NAFLD. However, the short therapeutic protocol of the trial represented a strong limitation to estimate the clinical effect of Aramchol on liver fat.
In a 1-year ARREST study [26], Aramchol was found to reduce liver fat and improve the biochemical markers of the liver. The drug was also found to reduce liver fibrosis in a dose-response pattern. Administration of Aramchol 600 mg demonstrated higher rates of NASH resolution and fibrosis reduction with excellent safety outcomes....
Conclusions
Aramchol was a safe and tolerable drug for use in patients with NAFLD. However, it was not superior to the placebo at reducing the biochemical liver markers."
Whatever, what is is, the stock is mired around 4 bucks and following two sizable reverse splits still has around 700 million shares outstanding, meaning the share count started in the billions. And here I thought out share count was high...
(4)
(0)